Core Viewpoint - Jingtai Holdings (02228) has seen a significant stock price increase, with a rise of nearly 8% during trading, currently up 6.12% at HKD 11.09, with a trading volume of HKD 1.26 billion [1] Group 1: Company Overview - Shenwan Hongyuan released a research report highlighting Jingtai Holdings' comprehensive coverage from physical computing to early-stage drug research automation, with core technologies including physical computing, AI, and robotics [1] - The company's business has expanded from AI drug development to a broader "AI4S" platform, indicating strong technological breadth and platform value [1] Group 2: Market Insights - The market's understanding of the technology transferability from AI pharmaceuticals to AI4S is insufficient, and there is a lack of recognition regarding the market potential of AI4S [1] - The perception of Jingtai Technology's technological leadership is still below expectations, indicating potential for market re-evaluation [1] Group 3: Operational Efficiency - The establishment of a closed-loop between dry and wet laboratories has effectively enhanced research and development efficiency [1] - Long-term data accumulation from wet laboratories will assist the company in optimizing predictive models [1]
港股异动 | 晶泰控股(02228)盘中涨近8% 机构称市场对晶泰科技的技术领先优势认知仍有预期差